Clinical trial OBT076-001
A Phase I/Ib, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors. (OBT076-001)
| Organ | Multiple |
|---|---|
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/1b |
| Academic trial | Non |
| Sponsor | Oxford BioTherapeutics |
| EudraCT Identifier | 2022-002386-14 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04064359 |
| Last update |